Testing a new inhaled powder for pulmonary arterial hypertension

Plain-English translation of NCT07481981 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new medication called (TPIP) as a treatment for pulmonary arterial hypertension—a serious condition where blood pressure in the arteries of the lungs becomes dangerously high. Researchers want to see if taking this medication once a day by inhaling it as a powder helps people with this condition exercise more easily and feel better. The trial will compare the medication against a placebo (a dummy treatment with no active ingredient) to see if it truly makes a difference.

Currently, people with pulmonary arterial hypertension have limited treatment options, and many still struggle with shortness of breath and difficulty exercising even while on existing medications. This trial is exploring whether the new treatment could help improve exercise ability and quality of life for patients who haven't had enough improvement with their current medicines.

Do you qualify?

You likely qualify if…

you have been diagnosed with pulmonary arterial hypertension (PAH) at least 3 months before screening, including idiopathic PAH, heritable PAH, drug-induced PAH, connective tissue disease-related PAH, or certain congenital heart disease-related PAH
you are already taking 1 to 3 standard PAH medications (such as endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, guanylate cyclase stimulators, or activin signaling inhibitors) on a stable dose for at least the last 30 days
you are in WHO or NYHA functional class II–IV (meaning you experience symptoms during daily activities or at rest)
you can walk between 150 and 450 meters in a 6-minute walk test
you have had recent heart catheterization showing specific blood pressure and resistance measurements in your lungs that confirm your PAH diagnosis

You likely don't qualify if…

you have pulmonary hypertension caused by left heart disease, lung disease, blood clots, or other rare causes not listed in the inclusion criteria
you have significant left heart disease, heart valve problems, or unstable heart conditions
you have had major bleeding or are at high risk for serious bleeding (especially if you are taking certain bleeding-risk medications)
you have airflow obstruction or significant lung disease that would make inhaling a powder unsafe

What participation looks like

Participants will attend a screening visit for heart tests and measurements, then return to receive their assigned treatment (either the new medication or placebo) to inhale once daily for 24 weeks. Starting at a low dose, the medication dose may be gradually increased based on how well you tolerate it, up to a maximum dose. You will have regular follow-up visits to check how you're doing, repeat the 6-minute walk test, and monitor for any side effects.

AI-generated summary from trial data · Sep 20, 2026 · Not medical advice

Trial locations(26 sites)

United States

USA012, Los Angeles, California

USA008, Santa Barbara, California

USA005, Torrance, California

USA010, Kansas City, Kansas

USA028, Omaha, Nebraska